A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases

Self/Nonself - Immune Recognition and Signaling

Volumn 2, Issue 1, 2011, Pages 35-42

  Sha, Yonggang ^a   Markovic Plese, Silva ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Il 1; IL 1R1; Multiple sclerosis; Th17 cells

Indexed keywords

CORTICOSTEROID; I KAPPA B; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON BETA SERINE; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 22; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C FOS; PROTEIN C JUN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN CONJUGATING ENZYME 13; UBIQUITIN CONJUGATING ENZYME E2; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BINDING AFFINITY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GENE DELETION; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INNATE IMMUNITY; LIGAND BINDING; MACROPHAGE; MUCKLE WELLS SYNDROME; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH17 CELL;

EID: 79960343317     PISSN: 19382030     EISSN: 19382049     Source Type: Journal    
DOI: 10.4161/self.2.1.15639     Document Type: Review

References (59)

1. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010; 3:1-6.
2. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-50.
3. Weber A, Wasiliew P, Kracht M. Interleukin-1beta (IL-1beta) processing pathway. Sci Signal 2010; 3:1-2.
4. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201:1355-9.
5. Dinarello CA. The many worlds of reducing interleukin- 1. Arthritis Rheum 2005; 52:1960-7.
6. Sriskantharajah S, Ley SC. Cell biology. Turning off inflammation signaling. Science 2010; 327:1093-4.
7. Mills KH, Dunne A. Immune modulation: IL-1, master mediator or initiator of inflammation. Nat Med 2009; 15:1363-4.
8. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009; 30:576-7.
9. Rao DA, Tracey KJ, Pober JS. IL-1alpha and IL-1beta are endogenous mediators linking cell injury to the adaptive alloimmune response. J Immunol 2007; 179:6536-46.
10. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA 2009; 106:7119-24.
11. Matsuki T, Nakae S, Sudo K, Horai R, Iwakura Y. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int Immunol 2006; 18:399-407.
12. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003; 100:5986-90.
13. Eriksson U, Kurrer MO, Sonderegger I, Iezzi G, Tafuri A, Hunziker L, et al. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J Exp Med 2003; 197:323-31.
14. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191:313-20.
15. Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, et al. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin- 1 receptor pathway and mTOR kinase activation. Immunity 2010; 32:54-66.
16. Quiniou C, Sapieha P, Lahaie I, Hou X, Brault S, Beauchamp M, et al. Development of a novel noncompetitive antagonist of IL-1 receptor. J Immunol 2008; 180:6977-87.
17. Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360:2438-44.
18. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426-37.
19. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206:1029-36.
20. Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojsavljevic N, et al. The analysis of IL-1beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol 2009; 207:101-6.
21. de Jong BA, Huizinga TW, Bollen EL, Uitdehaag BM, Bosma GP, van Buchem MA, et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002; 126:172-9.
22. Liu JS, Amaral TD, Brosnan CF, Lee SC. IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. J Immunol 1998; 161:1989-96.
23. Slack JL, Schooley K, Bonnert TP, Mitcham JL, Qwarnstrom EE, Sims JE, et al. Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to proinflammatory signaling pathways. J Biol Chem 2000; 275:4670-8.
24. Sims JE, March CJ, Cosman D, Widmer MB, MacDonald HR, McMahan CJ, et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988; 241:585-9.
25. McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 1991; 10:2821-32.
26. Colotta F, Re F, Muzio M, Bertini R, Polantarutti N, Sironi M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993; 261:472-5.
27. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-147.
28. Wang D, Zhang S, Li L, Liu X, Mei K, Wang X. Structural insights into the assembly and activation of IL-1beta with its receptors. Nat Immunol 2010; 11:905-11.
29. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343:336-40.
30. Elzinga BM, Twomey C, Powell JC, Harte F, McCarthy JV. Interleukin-1 receptor type 1 is a substrate for gamma-secretase-dependent regulated intramembrane proteolysis. J Biol Chem 2009; 284:1394-409.
31. Twomey C, Qian S, McCarthy JV. TRAF6 promotes ubiquitination and regulated intramembrane proteolysis of IL-1R1. Biochem Biophys Res Commun 2009; 381:418-23.
32. Kobayashi T, Walsh MC, Choi Y. The role of TRAF6 in signal transduction and the immune response. Microbes Infect 2004; 6:1333-8.
33. Zhang X, Shephard F, Kim HB, Palmer IR, McHarg S, Fowler GJ, et al. TILRR, a novel IL-1RI co-receptor, potentiates MyD88 recruitment to control Rasdependent amplification of NFkappaB. J Biol Chem 2010; 285:7222-32.
34. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NFkappaB induction by TNF, CD95 and IL-1. Nature 1997; 385:540-4.
35. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
36. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942-9.
37. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950-7.
38. Lee WW, Kang SW, Choi J, Lee SH, SHa K, Eynon EE, et al. Regulating human Th17 cells via differential expression of IL-1 receptor. Blood 2010; 115:530-40.
39. Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG, Shevach EM. Selective expression of latencyassociated peptide (LAP) and IL-1 receptor type I/ II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 2009; 113:5125-33.
40. Jacobs CA, Baker PE, Roux ER, Picha KS, Toivolla B, Waugh S, et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1alpha and suppressed by soluble IL-1 receptor. J Immunol 1991; 146:2983-9.
41. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37:424-35.
42. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle RC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203:1685-91.
43. Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, et al. STAT3 and NFkappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonistdeficient mice. J Immunol 2006; 176:5652-61.
44. Badovinac V, Mostarica-Stojkovic M, Dinarello CA, Stosic-Grujicic S. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol 1998; 85:87-95.
45. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 2007; 149:217-25.
46. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmster GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48:927-34.
47. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007; 204:2131-44.
48. Smeets RL, Joosten LA, Arntz OJ, Bennink MB, Takashi N, Carlsen H, et al. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum 2005; 52:2202-11.
49. Netea MG, Kullberg BJ, Boerman OC, Verschueren I, DInarello CA, Van der Meer JW. Soluble murine IL-1 receptor type I induces release of constitutive IL-1 alpha. J Immunol 1999; 162:4876-81.
50. Loiarro M, Ruggiero V, Sette C. Targeting TLR/IL-1R signaling in human diseases. Mediators Inflamm 2010; 2010:674363.
51. Garlanda C, Riva F, Polentarutti N, Buracchi C, Sironi M, De Bortoli M, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 2004; 101:3522-6.
52. Qin J, Qian Y, Yao J, Grace C, Li X. SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem 2005; 280:25233-41.
53. Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, et al. SIGIRR, a negative regulator of Toll-like receptorinterleukin 1 receptor signaling. Nat Immunol 2003; 4:920-7.
54. Bozza S, Zelante T, Moretti S, Bonifazi P, DeLuca A, D'Angelo C, et al. Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. J Immunol 2008; 180:4022-31.
55. O'Neill LA. SIGIRR puts the brakes on Toll-like receptors. Nat Immunol 2003; 4:823-4.
56. Watson MB, Costello DA, Carney DG, McQuillan K, Lnch MA. SIGIRR modulates the inflammatory response in the brain. Brain Behav Immun 2010; 24:985-95.
57. Comabella M, Julia E, Tintore M, Brieva L, Tellez N, Rio J, et al. Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferonbeta-1b in patients with progressive multiple sclerosis. J Neurol 2008; 255:1136-41.
58. Heesen C, Sieverding F, Buhmann C, Gbadamosi J. IL-1ra serum levels in disease stages of MS-a marker for progression? Acta Neurol Scand 2000; 101:95-7.
59. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cellinduced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA 2009; 106:4355-9.